About Hue Clinical.
India-anchored. Pre-launch.

Hue Clinical Pvt. Ltd. is building an AI-native cancer intelligence platform — a CDSCO Class C IVD AI device that reads molecular signatures from the H&E slide every Indian cancer patient already has. Solo founder through M3. Bengaluru, India.

95% of Indian cancer patients are treated without molecular testing. The signature is already on their biopsy slide; the workflow to read it at scale has not existed. We are being built for that gap.

Two revenue tracks: a B2B diagnostics search layer for Indian labs, and an AI-first CRO engine for pharma sponsors. India-anchored through M30, US whitespace at Series B, EU regulated at Series C.

For pharma medical affairs, R&D, academic pathology, or clinical advisory: kaustubh@hueclinical.com.